An A3 Executive Reference (2 pages) Japan rewards programs that are sequenced, evidenced, and locally socialized. […]
Cracking Japan’s Pharma Ecosystem: Field Notes from ~20 Years in the Trenches Japan rewards sequencing, proof, […]
Japan’s IVD sector remains highly structured and closely governed, benefiting from a mature healthcare infrastructure and […]
Navigating Japan’s life sciences sector successfully hinges on more than just excellent science or a meticulously […]
It started with a headline I read on the train to kendo practice. AstraZeneca is setting […]
Japan has set ambitious goals to advance its bioeconomy, aiming to integrate biotechnology across various sectors […]
BioStock Global Forum 2024 – May 30, Part II Watch the keynote speech, including the Q&A […]
The shift from using AI as an operational tool to embedding it as a central strategic […]
Understanding the MAH Japan System In Japan, the Marketing Authorization Holder (MAH) is central in the […]
Japanese Market Opportunities in AI-Driven Elderly Care: Living, Health, and Medication Management The silver economy of […]